This article is more than 5 years old. Information may no longer be current.
Flexion Therapeutics launches first extended-release injection to treat OA knee pain
Flexion Therapeutics Inc. announced the full commercial launch of Zilretta for the management of pain associated with osteoarthritis of the knee.
The first and only extended-release, intra-articular injection for OA knee pain, Zilretta is a non-opioid medicine that employs Flexion’s proprietary microsphere technology to provide pain relief for 12 weeks, according to a company press release. The release noted Zilretta received FDA approval on Oct. 6 and has been available on a limited basis since Oct. 23.
“We have assembled a remarkable team of musculoskeletal business managers, and last week they concluded their training at the Zilretta national launch meeting,” Michael Clayman, MD, president and CEO of Flexion, said in the release. “We have already begun the process of informing and educating physicians about the important role Zilretta can play in the management of OA knee pain. With its extended-release microsphere formulation, we believe Zilretta holds the potential to disrupt the current treatment paradigm, and we are thrilled that it is now broadly available for the millions of American confronting this relentless disease.”
Reference: